Florida Cancer Specialists & Research Institute (FCS) announced on June 9, 2025, the launch of liquid biopsy capabilities, enhancing its genomic testing to advance cancer care. As part of this expansion, FCS recently acquired the Illumina NovaSeq, which allows for the sequencing of many more samples more deeply and with faster turnaround times.
The adoption of Illumina's NovaSeq system by FCS, a statewide practice serving over 102,000 patients annually, underscores the increasing integration of advanced genomic testing in community oncology. FCS has expanded its next-generation sequencing (NGS) capabilities since 2021, processing over 16,000 molecular tests at its in-house laboratory.
This strategic investment by FCS highlights the value proposition of Illumina's instruments in providing rapid genetic information for various advanced cancers, aiding physicians in assessing and targeting treatments. The ability to incorporate patient clinical information into the analysis delivers tailored insights, driving better decisions and outcomes for cancer patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.